Our Mission
We exist at the frontier of possibility — where engineering meets biology, where precision meets compassion. The Greenford Nano and Cancer Foundation is committed to accelerating the translation of nanotechnology-based discoveries into real-world cancer solutions. We fund bold science, support the next generation of researchers, and stand alongside every patient waiting for a better answer.
Our Vision
To establish a global standard in cancer care where nanotechnology-enabled early detection and highly targeted treatments render conventional, systemically toxic therapies obsolete. We envision a future where precision medicine is not a luxury, but a standard of care accessible to every patient — regardless of geography or economic circumstance.
What We Research
At the Nanoscale, Cancer Has Nowhere to Hide
Our programs investigate three critical frontiers of nano-oncology: detecting cancer earlier than ever, delivering therapeutics with unprecedented precision, and exploring nanoparticle-immune system interactions.
Nano-Enabled Diagnostics
Nanosensor platforms capable of detecting cancer biomarkers at concentrations orders of magnitude below current clinical thresholds — enabling earlier, more accurate diagnosis.
Targeted Drug Delivery
Lipid nanoparticles, polymeric nanoparticles, and dendrimers engineered to accumulate at tumor sites, delivering therapeutic payloads directly to malignant cells while sparing healthy tissue.
Nano-Immunotherapy
Nanoparticle-based adjuvants and antigen delivery systems that prime, amplify, and direct the immune response against tumors — opening new frontiers in personalized cancer immunotherapy.
How We Work
A Complete Ecosystem of Support
Beyond the laboratory, the Foundation builds infrastructure that moves science from bench to bedside — funding researchers, supporting patients, and building partnerships.
Funding & Grants
Competitive grants supporting nano-oncology researchers globally.
Patient Support
Plain-language guides, clinical trial directories, and advisory sessions.
Education & Outreach
Public lectures, school programs, and digital resources for all.
Academic Partnerships
Formal collaboration agreements with leading universities worldwide.
Leadership
Guiding the Future of Oncology
Message from the Chairman
"Our commitment to bridging the gap between nanotechnology and clinical oncology is unwavering. We envision a future where precision medicine is not a luxury, but a standard accessible to everyone. By supporting brilliant minds and bold science, we are actively engineering that future."
Chairman, Greenford Nano and Cancer Foundation
Message from the Secretary General
"Translating microscopic discoveries into massive leaps for cancer care requires relentless collaboration. Through strategic partnerships, rigorous grant programs, and the incredible support of our donors, we are transforming hope into tangible therapies."
Secretary General, Greenford Nano and Cancer FoundationWho We Are
Our Mission & Vision
The Greenford Nano and Cancer Foundation is an independent, nonprofit research foundation dedicated to accelerating the development of nanotechnology-based approaches to cancer prevention, diagnosis, and treatment. We sit at a uniquely consequential intersection — between the precision of nanoscale engineering and the urgency of oncology — and we believe that this intersection holds some of the most promising answers to one of humanity's most enduring challenges.
Cancer is not a single disease. It is hundreds of distinct conditions, each defined by its own molecular signature. Nanotechnology, with its capacity for molecular-level engineering and targeting, is uniquely suited to this diversity. We can engineer particles that recognize specific tumor markers. We can design delivery vehicles that release their therapeutic payload only upon contact with the acidic microenvironment of a malignant cell.
That is the vision that drove the establishment of this Foundation, and it is the vision that drives our work today — from Kushtia, Bangladesh, to global oncology centers.
"At the nanoscale, we are not simply improving existing treatments — we are creating a fundamentally new vocabulary for medicine. One molecule at a time."
— Founding Scientific Director
Based in Kushtia, Bangladesh, we operate as a globally-connected research foundation, funding projects across Asia, Europe, and North America while maintaining our commitment to equitable access for patients in all regions.
Core Values
What We Stand For
Scientific Integrity
Every conclusion we publish must be grounded in rigorous, reproducible science. We hold ourselves and our partners to the highest standards of scientific conduct and transparent reporting.
Translational Purpose
We are not satisfied with discovery for its own sake. Our goal is translation — moving findings from the laboratory bench to clinical practice, from publication to patient benefit.
Equitable Access
The benefits of scientific progress should not be confined to wealthy nations. We are committed to developing solutions that can be manufactured affordably and deployed in resource-limited settings.
Compassionate Partnership
Behind every data point is a patient — a person with a family, with fears, with hope. Our programs and culture are shaped by a deep commitment to empathy, dignity, and respect.
Governance & Accountability
The Foundation is governed by an independent Board of Trustees comprising leading figures in oncology, nanotechnology, bioethics, philanthropy, and patient advocacy. Our Scientific Advisory Board provides expert guidance on research priorities and grant evaluation.
We publish an Annual Report detailing our expenditures, research outcomes, and organizational performance, and we are fully compliant with all applicable charity law and financial reporting requirements.
Financial Transparency
We maximize the impact of every donation. Resource allocation for the current fiscal year:
-
80%
Translational Research & GrantsDirect funding for laboratory programs and investigator grants
-
15%
Patient Support & OutreachResources, education, and advisory programs
-
5%
Administrative & GovernanceOperations, legal, and compliance
Active Research Portfolio
Our Research
Our portfolio spans nano-diagnostics, targeted drug delivery, and nanoparticle-immune system interactions, bridging fundamental nanomaterials science and clinical oncology.
SERS Nanoparticle Platform for Liquid Biopsy in Early-Stage Breast Cancer
Development and clinical validation of a surface-enhanced Raman scattering (SERS) nanoparticle probe array for simultaneous detection of breast-cancer-associated protein biomarkers in peripheral blood at sub-picomolar concentrations.
pH-Responsive Lipid Nanoparticle Delivery in Pancreatic Adenocarcinoma
Design, synthesis, and in vivo evaluation of pH-sensitive lipid nanoparticles for co-delivery of tumour-suppressor mRNA and pro-apoptotic siRNA, targeting the characteristically acidic tumour microenvironment.
Dendrimer-Mediated Checkpoint Inhibitor Delivery for TIL Activation
Investigation of PAMAM dendrimer carriers for targeted intratumoural delivery of anti-PD-L1 antibody fragments, aiming to amplify tumour infiltrating lymphocyte activity while minimising systemic immunotoxicity.
Iron Oxide Nanoparticle Contrast Agents for MRI-Guided Glioblastoma Definition
Clinical feasibility study evaluating USPIO nanoparticle-enhanced MRI for improved delineation of the infiltrative margin of glioblastoma multiforme for stereotactic radiosurgery planning.
Publications Repository
Selected Peer-Reviewed Publications
The following publications represent peer-reviewed output of research conducted or funded by the Foundation. DOI links direct to respective journal pages.
Scientific Team
Principal Investigators
Prof. A. Researcher
Principal Investigator · Nano-Diagnostics BiosensingDr. B. Researcher
Principal Investigator · Drug Delivery Lipid NanoparticlesDr. C. Researcher
Early Investigator · Immunotherapy ImmunotherapyExpansion Goals 2026–2030
The Foundation has adopted a five-year strategic plan to substantially expand its research capacity and translational impact:
- Global Clinical Trial Networks: Establish partnerships with 15 international cancer centers to accelerate Phase II trials.
- Open-Source Nanoscience: Launch a shared data repository for early-stage nanoparticle cytotoxicity results.
- Patient Accessibility: Develop supply-chain strategies to ensure affordability of nanomedicines in developing regions.
- Early Investigator Pipeline: Expand the Early Investigator Award program to support 20 new junior faculty positions by 2028.
- Regulatory Pathways: Engage proactively with FDA, EMA, and DGDA on regulatory frameworks for nanoparticle-based therapeutics.
Our Programs
What We Do
Beyond the laboratory, the Foundation builds a complete ecosystem of support — funding researchers, providing practical guidance for patients, and building the institutional partnerships that translate science into medicine.
Funding & Grants
Research Grant Programs
Foundation Research Grant — Flagship Program
The Foundation Research Grant is our flagship funding mechanism, providing substantial multi-year support to established research teams working on high-impact nano-oncology projects. Awards support laboratory operations, personnel, equipment acquisition, and dissemination activities.
Early Investigator Award
Supporting postdoctoral researchers and junior faculty in the first five years of their independent research career who are establishing nano-oncology research programs. These awards provide seed funding to generate preliminary data for larger grant applications to national funding bodies such as NIH, UKRI, and ERC.
International Collaboration Supplement
Additional funding for existing Foundation-funded projects that establish formal collaborative partnerships with research institutions in low- and middle-income countries (LMICs), in support of the Foundation's commitment to equitable access and global research capacity building.
Patient Support
We Are Here for You
A cancer diagnosis changes everything — and it raises questions that can feel overwhelming, especially when they involve new and unfamiliar treatments. Our resources help patients and their families understand the science, locate relevant clinical trials, and connect with the support they need.
Patient Explainer Guides
Plain-language guides covering how nanoparticle drug delivery works, what clinical trials involve, and how to talk to your oncologist about emerging treatment options.
Clinical Trial Finder
A curated, regularly updated directory of clinical trials investigating nanotechnology-based cancer treatments, categorised by cancer type, treatment stage, and geographic location.
Ask a Scientist
Submit questions about nanotechnology-based cancer research and receive written responses from our scientific team within 5 business days. Not a medical consultation — a science clarity service.
Education & Outreach
Spreading the Science
Public Webinar Series
"Nano & Cancer: The Science Explained" — free monthly online presentations by leading researchers. Sessions are recorded and freely available on our website and YouTube channel. No scientific background required.
Research Digest Newsletter
Our monthly newsletter provides plain-language summaries of significant recent publications in nano-oncology, curated and explained by our scientific communications team. Subscribe to receive it in your inbox.
Transparency
Annual Report
Review our milestones, funded projects, and financial health in our comprehensive yearly review. Every figure is independently audited.
Active Research Projects
Across three nano-oncology focus areas
Publications
In leading peer-reviewed oncology journals
To Direct Research
Of every donation goes straight to programs
Media & Updates
Latest News & Coverage
Phase II Trials Begin for SERS Biosensor Platform
Our flagship diagnostic platform has successfully initiated Phase II clinical trials, testing early-stage biomarker detection across multiple clinical sites. The SERS nanoparticle probe array is designed for the simultaneous detection of breast-cancer-associated protein biomarkers in peripheral blood at sub-picomolar concentrations. If successful, this trial will pave the way for liquid biopsies that can detect tumor presence years before conventional imaging.
The research team has partnered with leading oncology centers across Europe to recruit a diverse cohort of patients. Results from the first stage of Phase II are expected to be published early next year.
New $1.2M Multi-Year Grant Awarded for Pancreatic Cancer Research
The Foundation has awarded a major $1.2M grant to expand research into pH-responsive lipid nanoparticles for targeted pancreatic cancer treatments. Led by Dr. B. Researcher, the study will focus on co-delivery of tumour-suppressor mRNA and pro-apoptotic siRNA, targeting the characteristically acidic tumour microenvironment of pancreatic adenocarcinoma.
This funding ensures the laboratory has the resources required to scale their in-vivo models over the next three years, moving closer to translational clinical applications.
Foundation Launches Patient Support Resource Hub
We are proud to announce the launch of our expanded Patient Support Resource Hub — a new, dedicated section of our website providing plain-language guides, a curated clinical trial finder, and our Ask a Scientist advisory service for patients and families navigating nano-oncology treatment options.
The hub was developed in consultation with patient advocacy groups and reviewed by clinical oncologists for accuracy and accessibility.
Partnerships
Build the Future of Cancer Research Together
Cancer is too complex a challenge for any single institution to solve alone. We actively seek collaborative relationships with universities, academic medical centres, pharmaceutical and biotechnology companies, and government research agencies.
Academic & Research Institutions
We formalise research collaborations through structured agreements governing intellectual property, data sharing, publication rights, and financial arrangements.
- ✦ Research Collaboration Agreements
- ✦ Student & Postdoctoral Placement Program
- ✦ Joint Grant Applications (NIH, UKRI, ERC, DGDA)
- ✦ Co-supervised Doctoral Programs
Corporate & Industry Partners
We welcome corporate sponsors, technology licensing partners, and philanthropic corporate partnerships, all structured to maintain complete research independence.
- ✦ Research Sponsorship (independence guaranteed)
- ✦ Technology Licensing & Commercialisation
- ✦ CSR & Employee Giving Programs
- ✦ Cause-Related Marketing Partnerships
Memorandum of Understanding (MOU) Request
Initiate a formal collaboration by submitting a preliminary MOU request. Our legal and partnerships team will review and respond within 5 business days.
Direct partnership enquiries:
partnerships@greenfordnanocancer.org
Get in Touch
Contact Us
Have questions about our research, programs, partnerships, or donations? Our team typically responds within 2 business days.
Address
34/1 S.B. Road, Aruapara, Kushtia - 7000
Khulna Division, Bangladesh
General Enquiries
info@greenfordnanocancer.org
Partnerships: partnerships@greenfordnanocancer.org
Phone
+880 1XXX-XXXXXX
Support Our Mission
Fund the Science That Changes Everything
Somewhere, a researcher is testing a nanoparticle that may one day find a cancer that conventional imaging cannot. Your donation makes that research possible — and that hope real.
Make a Gift Online
Local Bank / MFS Transfer
Bangladesh Mobile Financial Services:
Nagad / bKash / Rocket / Upay:01789-XXXXXX
After sending, please submit your transaction details below for verification and to receive your donation receipt.
Your Impact
What your donation funds, directly:
Legacy & Planned Giving
A bequest or charitable trust is one of the most powerful ways to ensure your values shape the future of cancer research. Speak confidentially with our team.
Transparency & Accountability
At least 80% of every donation goes directly to research and programs. Full audited financials published annually.